About this trial
Inflammatory Bowel Disease (IBD) is a chronic relapsing condition that affects the gastrointestinal tract and is increasingly diagnosed in adolescents and young adults. Although anti-TNFα therapies are effective in reducing disease activity and improving quality of life, they are frequently associated with side effects such as fatigue, weight gain, and joint pain, which may be mitigated by regular physical activity.
Emerging evidence suggests that light to moderate physical activity may help reduce systemic and intestinal inflammation and improve IBD-related outcomes. However, access to structured physical activity programs remains limited, and personal or professional constraints may hinder participation.
This pilot study aims to assess the feasibility and impact of a remotely delivered Adapted Physical Activity (APA) program on the quality of life of patients with Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis. This study evaluates the effects of a 12-weeks remote APA intervention on quality of life as the primary outcome.
Secondary objectives include assessing changes in anxiety and depression, fatigue levels, IBD activity, and smoking behavior. The findings from this study may inform the development of scalable, non-pharmacological strategies to support symptom management and well-being in individuals with IBD.
Eligibility criteria
Qualifiers
Adults aged 18 years and older
Diagnosis of Inflammatory Bowel Disease (IBD) established for at least 6 months
Patient is motivated to participate in the Adapted Physical Activity (APA) program
Medical certificate confirming fitness to engage in remote physical activity
Disqualifiers
Patients under 18 years of age
Medical contraindication to physical activity
Total >1500 MET-min/week of vigorous activity on at least 3 days, OR
Total physical activity >3000 MET-min/week, regardless of distribution
Trial design
Treatments tested in this trial
- adapted physical activity
Treatment groups
Sponsors and collaborators
Raincy Montfermeil Hospital Group
Lead sponsor
Janssen Cilag S.A.S.
Collaborator